Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions

Developmental Neurorehabilitation

Volumn 13, Issue 1, 2010, Pages 31-36

  Howe, Warwick ^a   Davis, Elizabeth ^b   Valentine, Jane ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Adolescent; Chronic neurological; Fracture; Osteopenia; Paediatric; Pain; Pamidronate

Indexed keywords

ANTIPYRETIC AGENT; CALCIUM; PAMIDRONIC ACID;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE PAIN; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG INFUSION; FEMALE; FEMUR NECK; FEVER; FRACTURE; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPOCALCEMIA; KIDNEY TUBULE DISORDER; KIDNEY TUBULE LEAK; LUMBAR SPINE; MALE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; OSTEOGENESIS IMPERFECTA; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUADRIPLEGIA; QUESTIONNAIRE; SCHOOL CHILD; SPINAL MUSCULAR ATROPHY; WELLBEING;

ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CHILD; DIPHOSPHONATES; FEMALE; HEALTH STATUS; HUMANS; MALE; PAIN; PAIN MEASUREMENT; PATIENT SELECTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 75149155088     PISSN: 17518423     EISSN: 17518431     Source Type: Journal    
DOI: 10.3109/17518420903236270     Document Type: Article

References (21)

1. Henderson RC, Lark RK, Gurka MJ, Worley G, Fung EB, Conaway M, Stallings VA, Stevenson RD. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002;110:e5.
2. Khoury DJ, Szalay EA. Bone mineral density correlation with fractures in nonambulatory pediatric patients. Journal Pediatric Orthopedics 2007;27:562-566.
3. King W, Levin R, Schmidt R, Oestreich A, Heubi JE. Prevalence of reduced bone mass in children and adults with spastic quadriplegia. Developmental Medicine and Child Neurology 2003;45:12-16.
4. Roberts D, Lee W, Cuneo RC, Wittmann J, Ward G, Flatman R, et al. Longitudinal study of bone turnover after acute spinal cord injury. Journal of Clinical Endocrinology Metabolism 1998;83:415-422.
5. Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J, Uebelhart D. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Archives of Physical Medicine and Rehabilitation 1999;80:243-251.
6. Szollar SM, Martin EM, Sartoris DJ, Parthemore JG, Deftos LJ. Bone mineral density and indexes of bone metabolism in spinal cord injury. American Journal of Physical Medicine and Rehabilitation. 1998;77:28-35.
7. Kannisto M, Alaranta H, Merikanto J, Kroger H, Karkkainen J. Bone mineral status after pediatric spinal cord injury. Spinal Cord 1998;36:641-646.
8. Fewtrell MS, Prentice A, Jones SC, Bishop NJ, Stirling D, Buffenstein R, Lunt M, Cole TJ, Lucas A. Bone mineralization and turnover in preterm infants at 8-12 years of age: The effect of early diet. Journal of Bone Mineral Research 1999;14:810-820.
9. Henderson RC, Kairalla J, Abbas A, Stevenson RD. Predicting low bone density in children and young adults with quadriplegic cerebral palsy. Developmental Medicine and Child Neurology 2004;46:416-419.
10. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial. Journal of Pediatrics 2002;141:644-651.
11. Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: A pilot study. Developmental Medicine and Child Neurology 2006;48: 709-712.
12. Bachrach SJ, Kecskemethy HH, Harcke HT, Lark RK, Miller F, Henderson RC. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy. Journal of Clinical Densitometry 2006;9:167-174.
13. Houlihan CM, O'Donnell M, Conaway M, Stevenson RD. Bodily pain and health-related quality of life in children with cerebral palsy. Developmental Medicine and Child Neurology 2004;46:305-310.
14. Msall ME, DiGaudio K, Duffy LC, LaForest S, Braun S, Granger CV, WeeFIM. Normative sample of an instrument for tracking functional independence in children. Clinical Pediatrics (Philadelphia) 1994;33:431-438.
15. Msall ME, DiGaudio K, Rogers BT, LaForest S, Catanzaro ML, Campbell J, Wilczenski F, Duffy LC. The Functional Independence Measure for Children (WeeFIM): Conceptual basis and pilot use in children with developmental disabilities. Clinical Pediatrics 1994;33: 421-430.
16. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology 1997;39: 214-223.
17. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opinion in Drug Safety 2007;6:663-672.
18. Stratton JD, Warwicker P. Relapse of nephrotic syndrome triggered by biphosphonates. Nephrology Dialysis Transplant 2002;17:1856-1857.
19. Szeto CC, Chow KM. Nephrotoxicity related to new therapeutic compounds. Renal Failure 2005;27:329-333.
20. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(Suppl 4):28-37.
21. Henderson R. Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children. Developmental Medicine and Child Neurology 2006;48:708.